By Chris Wack

Flora Growth Corp. said it has signed an agreement to begin scientific clinical trials globally.
The cannabis company said the focus of the study will be the use of cannabinoids in patients suffering from fibromyalgia, or chronic pain, with the primary research sites located in the U.S. and the U.K.

Flora Pharma, the company’s newest division, said it expects to fast track traditional Food and Drug Administration timelines by running phase trials in parallel.
The human pilot study will begin in the U.K. in coordination with an internationally recognized clinical research group based at the University of Manchester, while parallel molecular and pharmacokinetic studies will be conducted in the U.S., the company said.
Flora Growth shares were up 5% to $5.54 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com